white → green2 → brown2
dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.
DOM
2,5-Dimethoxy-4-methylamphetamine
STP, Serenity, Tranquility, and Peace
DOM is a psychedelic amphetamine of the DOx familycitation needed, first synthesized by Alexander Shulgin in 1963 and later documented in his 1991 book PiHKAL. It gained notoriety during the 1967 Summer of Love in San Francisco, where high-dosed tablets caused hospitalizations due to its characteristically slow onset and extremely long duration1. Shulgin considered it one of his "magical half-dozen" — his personal favorite compounds. It produces stimulant effects at lower doses and hallucinogenic effects at higher dosescitation needed.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Threshold~0.5 mg
Light1-2.5 mg
Moderate2.5-5 mg
Strong5-7.5 mg
Heavy7.5+ mg
DOM exhibits pronounced dose-sensitivity and is considerably more potent by weight than most other phenethylamine psychedelics. Tolerance to its effects builds quickly following use and typically requires around one week without further dosing to fully reset.
Duration
Onset60-120 minutes
Come Up2-3 hours
Peak6-8 hours
Offset3-5 hours
After Effects4-16 hours
Total12-16 hours
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
Effects vary widely by individual, dose, and context.
Physical
The physical effects of DOM can be broken down into several components which progressively intensify proportional to dosage.
Cognitive
The cognitive effects of DOM are described by many as a combination of extreme mental stimulation and a powerful enhancement of a person's current mental state.
Visual
Enhancements
DOM presents a full and complete array of possible visual enhancements.
Geometry
The visual geometry that is present throughout this trip can be described as more similar in appearance to that of 4-AcO-DMT or ayahuasca than that of LSD, 2C-B or 2C-I. It can be comprehensively described through its variations as intricate in style, equally algorithmic and abstract in form, equally synthetic and organic in style, structured in organization, brightly lit in lighting, multicoloured in scheme, glossy in shading, sharp in edges, large in size, fast in speed, smooth in motion, equal in rounded and angular corners, non-immersive in depth and consistent in intensity. Higher dosages are significantly more likely to result in states of Level 8A visual geometry over Level 8B.
Hallucinatory States
DOM produces a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of many other commonly used psychedelics. This holds particularly true in comparison to other substances within the phenethylamine family.
Auditory
The auditory effects of DOM are common in their occurrence and exhibit a full range of effects.
See also: Psychedelic Intensity Scale, Effects of psychedelics (visual, cognitive, miscellaneous)
Pharmacology
Pharmacodynamics
DOM selectively targets the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors as an agonist, with its psychedelic effects primarily attributed to 5-HT2A activation.citation needed Sources differ on whether DOM functions as a full or partial agonist at these receptors. R-(−)-DOM is the more active enantiomer.2 Outside of the 5-HT2 family, DOM is inactive as a monoamine reuptake inhibitor and releasing agentcitation needed and shows only very weak inhibition of MAO-A with no activity at MAO-B. Its high selectivity for the 5-HT2 receptor subfamily has made it a widely used pharmacological research tool, and it has also been reported to possess potent anti-inflammatory properties.
Pharmacokinetics
The pharmacokinetics of DOM have been only limitedly studied in humans. The drug undergoes demethylation, producing the pharmacologically active metabolites 2-O-desmethyl-DOM and 5-O-desmethyl-DOM, which may contribute to its delayed onset and long duration of action.citation needed There is also evidence suggesting that metabolic conversion may occur in the lungs prior to central nervous system activity. Approximately 5 to 20% of a dose is excreted unchanged.
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Unsafe
AvoidThere is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
2C-T-x compounds2C-x compounds5-MeO-xxT tryptaminesCaffeineCannabisDiphenhydramineMAOIsMDMAMephedroneMescalineMXENBOMe compoundsPregabalin
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Full Tolerance
Tolerance to the effects of DOM develops almost immediately after ingestion. Clinical studies have demonstrated that with daily administration over three consecutive days, subjective effects diminish dramatically—ranging from 'moderately strong' responses to complete absence of effects by the third day, with one subject actually sleeping through the experience.
Baseline Reset
Approximately 7 days of abstinence
Half Tolerance
Approximately 3 days
Cross Tolerance
Psychedelics (all serotonergic psychedelics will have reduced effects following DOM consumption)
Harm Potential
Addiction & Dependence
Psychological
Extremely LowDOM is not habit-forming and the desire to use it typically decreases with use. It exhibits a self-regulating quality that discourages compulsive redosing or frequent administration.
Physical
Extremely LowDOM is not physically addictive and does not produce physical dependence or withdrawal symptoms.
Toxicity
Cardiovascular
DOM produces pronounced cardiovascular stimulation including large increases in heart rate and blood pressure during intoxication;citation needed these effects are described as more worrisome than those seen with classic psychedelics like LSD, and severe vasoconstriction may develop at high doses.
Psychosis Risk
DOM can induce psychotic states particularly at high doses, manifesting as an amphetamine psychosis-like condition with bizarre, delusional, and sometimes violent behavior. Frequent use carries risk of persistent reality distortion and may trigger latent psychoses in predisposed individuals. The exceptionally long duration increases psychological burden and likelihood of adverse psychological reactions.
Seizure Risk
Seizures are a potential risk primarily at high or overdose-level doses. Those predisposed to seizures may be at elevated risk, particularly when DOM is combined with other substances that lower seizure threshold.
History & Culture
Discovery and Synthesis
DOM was first synthesized by Alexander Shulgin in 1963.3 The initial step of the synthesis was performed by his then fifteen-year-old son Theodore "Ted" Shulgin at Dow Chemical Company on June 22, 1963, during a brief period when the younger Shulgin had developed an…
Trip Reports
Loading related reports
Preparing section content
Still loading. Refresh if this section does not appear.
Legality
International
1961 Single Convention: DOM/STP is not scheduled.
1971 Convention on Psychotropic Substances: Schedule I.
1988 Convention: DOM/STP is not listed in precursor Tables I or II.
By Country
Illegal13
United StatesIllegal21 CFR § 1308.11(d)32
Current official legislation expressly controls DOM/STP in United States; unauthorised possession, supply, or manufacture is prohibited.
AustraliaIllegalAustralian Poisons Standard June 2026, Schedule 94
DOM is expressly listed in Schedule 9 of the current federal Poisons Standard, subject to the stated research exceptions.
AustriaIllegalAustrian Suchtgiftverordnung Annex V.15
The current RIS annex expressly names STP/DOM in V.1 under Austria's controlled-substance framework.
BelgiumIllegalBelgian Royal Decree and AFMPS Annex IIA6
The current AFMPS document is marked valid from 29/03/2026 and expressly identifies STP (DOM) in Annex IIA. The PDF is a non-official consolidated version; the underlying Royal Decree remains the formal instrument.
BrazilIllegalListed on Portaria SVS/MS nº 344 under the name 'STP'.7 Possession, production, and sale are prohibited.
CanadaSchedule IControlled substance under the Controlled Drugs and Substances Act.8 Possession, trafficking, and production are criminal offenses.
Czech RepublicIllegalGovernment Regulation No. 463/2013 Coll. on lists of addictive substances (Nařízení vlády č. 463/2013 Sb.), current e-Sbírka text effective 25 June 2026, Annex 4 (List No. 4 psychotropic substances), issued under § 44c(1) of Act No. 167/1998 Coll. on addictive substances; Czech Penal Code No. 40/2009 Coll., current e-Sbírka text effective 1 January 2026, §§ 283-284.9101112131415161718
DOM is prohibited in the Czech Republic.
GermanyIllegalBetäubungsmittelgesetz, Anlage I19
Current official legislation expressly controls DOM/STP in Germany; unauthorised possession, supply, or manufacture is prohibited.
LatviaSchedule IClassified as a Schedule I controlled substance under Latvian drug control legislation.21
New ZealandClass AControlled as a Class A substance, the most restrictive classification under New Zealand's Misuse of Drugs Act.22
RussiaSchedule IClassified as a Schedule I substance in the Russian Federation.23 Buying, selling, or possessing without a license is illegal.
SwitzerlandIllegalBetäubungsmittelverzeichnisverordnung (BetmVV-EDI, SR 812.121.11), consolidated standing 13 March 2026, Articles 1-2 and Annex 5 (Verzeichnis d); Betäubungsmittelkontrollverordnung (BetmKV, SR 812.121.1), consolidated standing 23 January 2023, Articles 3(2)(d) and 8; Betäubungsmittelgesetz (BetmG, SR 812.121), consolidated standing 1 September 2023, Articles 19 and 19a.249252627282930
DOM is listed as a prohibited controlled substance in Verzeichnis d.
United KingdomClass AControlled under the Misuse of Drugs Act 1971.31 Buying, selling, or possessing without a license is prohibited.citation needed
Controlled / restricted1
ItalyTabella IListed in Tabella I of the 'Tabelle delle sostanze stupefacenti e psicotrope'.20 Possession, purchase, and sale are illegal.citation needed
References
Source Pages
Citations
- Matthew J. Baggott. (2023). Learning about STP: A Forgotten Psychedelic from the Summer of Love. History of Pharmacy and Pharmaceuticals, 65(1), 93-116. https://doi.org/10.3368/hopp.65.1.931
- Shulgin AT, & Shulgin A. (1991). PiHKAL: A Chemical Love Story — #68 DOM. 637-642. https://www.erowid.org/library/books_online/pihkal/pihkal068.shtml12345
- Keeper Trout, & Paul F. Daley. (2024). The origin of 2,5-dimethoxy-4-methylamphetamine (DOM, STP). Drug Testing and Analysis. https://doi.org/10.1002/dta.36671234
- Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026. legislation.gov.au (n.d.). https://www.legislation.gov.au/F2026L00633/asmade/2026-05-28/text/original/epub/OEBPS/document_1/document_1.html1
- RIS Suchtgiftverordnung, Anlage 5, consolidated version dated 14 April 2026. ris.bka.gv.at (n.d.). https://ris.bka.gv.at/NormDokument.wxe?Abfrage=Bundesnormen&Anlage=5&Artikel=&FassungVom=2026-04-14&Gesetzesnummer=10011053&Paragraf=&Uebergangsrecht=1
- AFMPS Annex II consolidated reference, update valid from 29 March 2026. afmps.be (n.d.). https://www.afmps.be/sites/default/files/content/INSP/NARC/annex%20II_non%20official%20consolidated%20version.pdf1
- Portaria SVS/MS nº 344, de 12 de maio de 1998 – Lista F2 Substâncias Psicotrópicas Proscritas. (n.d.). https://bvsms.saude.gov.br/bvs/saudelegis/svs/1998/prt0344_12_05_1998_rep.html1
- Controlled Drugs and Substances Act (S.C. 1996, c. 19) – Schedule I. (n.d.). https://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-9.html1
- 2,5-Dimethoxy-4-Methylamphetamine — PubChem CID 85875. pubchem.ncbi.nlm.nih.gov (n.d.). https://pubchem.ncbi.nlm.nih.gov/compound/8587512
- PubChem PUG REST properties for DOM CID 85875. pubchem.ncbi.nlm.nih.gov (n.d.). https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/85875/property/IUPACName,MolecularFormula,MolecularWeight/JSON1
Further Reading
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass review
A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes8 human edits · latest
Times are UTCNewest first
31 July 2026
Lyrea · Updated the article
25 March 2026
Lyrea · Updated the article · also 2C-B, Alprazolam, MDMA
Josie Kins · Updated the article
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the DOM article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.
